TIMED BIORESORBABLE Y 90 MICROSPHERES FOR RADIOTHERAPY

Information

  • Research Project
  • 2538321
  • ApplicationId
    2538321
  • Core Project Number
    R43CA076860
  • Full Project Number
    1R43CA076860-01
  • Serial Number
    76860
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1997 - 27 years ago
  • Project End Date
    3/29/1998 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1997 - 27 years ago
  • Budget End Date
    3/29/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/29/1997 - 27 years ago
Organizations

TIMED BIORESORBABLE Y 90 MICROSPHERES FOR RADIOTHERAPY

DESCRIPTION: Leakage of radioactive material away from the injection site reduces therapeutic efficacy, induces undesirable damage to normal tissues, and increases the risk of side effects (dermitis, neuritis) and secondary neoplasia (leukemia and osteosarcoma). Insoluble glass or ceramic microspheres may contain radioactivity to the injection site and inhibit leakage, but may also later induce inflammation, deterioration of tissues, and fibrosis, or cause physical damage to healing/healed joints. These obstacles may be overcome with a new, timed- bioresorbable calcium phosphate microspheres. These microspheres can be made to maintain structural integrity for 30 days (11 physical half- lives for Y-90, i.e., decayed to negligible activity) before they begin to dissolve at a predetermined rate, leaving nothing in the patient to cause irritation, blockage or physical damage. The purpose of this project is to prepare and test Y-90-containing microspheres with pre- programmed bioresorption. Glass composition range and Y-90 solubility in glasses will be established. The in vitro properties of bioresorbable Y-90 calcium phosphate glass microspheres will be characterized so that follow-up tests can be conducted in laboratory animals. Applications of Y-90 microspheres include direct intratumoral injection (infusional brachytherapy) in treatment of cancers of liver, pancreas, brain, etc., and radiation synovectomy of rheumatoid arthritis.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    XL SCI-TECH, INC.
  • Organization Department
  • Organization DUNS
    931933824
  • Organization City
    RICHLAND
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    993541663
  • Organization District
    UNITED STATES